Medicovestor Rectangle.PNG
Medicovestor, Inc announces the completion of an oversubscribed Seed Financing round to advance its novel Antibody Drug-Conjugate (ADC) platforms
November 20, 2023 10:00 ET | Medicovestor Inc
Medicovestor excels in oversubscribed Seed funding for its novel Anti-Drug Conjugate (ADC) platforms, gearing up for Series A in H1 2024.
22157.jpg
Global Antibody Drug Conjugate (ADC) Competitive Landscape Report 2023: Company Analysis, Therapeutic Assessment, Pipeline Assessment, Inactive Drugs Assessment, Unmet Needs
November 17, 2023 08:13 ET | Research and Markets
Dublin, Nov. 17, 2023 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugate - Competitive landscape, 2023" report has been added to ResearchAndMarkets.com's offering. This report provides...
22157.jpg
Global CD19 Antibody Market Projected to Exceed $10 Billion by 2028, Driven by Promising Pipeline of Therapies
November 09, 2023 05:58 ET | Research and Markets
Dublin, Nov. 09, 2023 (GLOBE NEWSWIRE) -- The "Global CD19 Antibody Market & Clinical Pipeline Outlook 2028" report has been added to ResearchAndMarkets.com's offering. The global CD19...
22157.jpg
Global CD19 Antibody Market Set to Surpass $10 Billion by 2028: A Revolutionary Era in Immunotherapy
November 03, 2023 07:43 ET | Research and Markets
Dublin, Nov. 03, 2023 (GLOBE NEWSWIRE) -- The "Global CD19 Antibody Market and Clinical Pipeline Outlook 2028" report has been added to ResearchAndMarkets.com's offering. The global CD19 Antibody...
ptx-logo .png
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
November 01, 2023 16:05 ET | Prelude Therapeutics, Inc.; AbCellera
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
22157.jpg
Global Antibody Drug Conjugates Market Poised to Reach $19.8 Billion by 2028, Fueled by Increasing Cancer Prevalence and Clinical Advancements
October 26, 2023 07:33 ET | Research and Markets
Dublin, Oct. 26, 2023 (GLOBE NEWSWIRE) -- The "Global Antibody Drug Conjugates (ADC) Market by Product (Kadcyla, Enhertu, Padcev, Polivy), Linker Type (Cleavable, Non-Cleavable), Payload Type...
Elucida Oncology Logo.jpg
Elucida Oncology Presents Encouraging Clinical Data from Phase 1/2 Study of ELU001 in Solid Tumors Overexpressing Folate Receptor Alpha at ESMO Congress 2023
October 23, 2023 08:00 ET | Elucida Oncology, Inc
Anti-tumor activity observed across all levels of folate receptor alpha (“FRα”) expression89% of patients with cancers expressing FRα showed stable disease or a partial response following treatment...
ADC Technology Market: Focus on ADC Linker and ADC Conjugation Technologies
ADC (Antibody Drug Conjugates) Markets, 2035
October 17, 2023 07:38 ET | Research and Markets
Dublin, Oct. 17, 2023 (GLOBE NEWSWIRE) -- The "ADC Technology Market: Focus on ADC Linker and ADC Conjugation Technologies (2nd Edition) - Distribution by Generation of ADC Technology, Type of...
TIP_link_300x300.jpg
Antibody Drug Conjugates Market Revenue to Hit $29.6 Billion, Globally, by 2030 – Exclusive Study by The Insight Partners
October 09, 2023 08:04 ET | The Insight Partners
Pune, India, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Antibody drug conjugates (ADC) are one of the fastest growing anticancer drugs. It is typically composed of a monoclonal antibody (mAbs) covalently...
84bd90f5-4a1f-42a8-8eb1-5cb062a0b6ac.png
Antibody Drug Conjugates Market to increase by USD 34.7 Billion by 2032 || North America led with a 40% revenue share in 2022
September 25, 2023 09:23 ET | Market.Us
New York, Sept. 25, 2023 (GLOBE NEWSWIRE) -- According to a recent report by Market.us, the Global Antibody Drug Conjugates Market size is expected to be worth around USD 34.7 Billion by 2032 from...